PMID- 34310833
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 10
DP  - 2021 Oct
TI  - Diagnostic performance of miR-214, BNP, NT-proBNP and soluble ST2 in acute heart 
      failure.
PG  - e14643
LID - 10.1111/ijcp.14643 [doi]
AB  - PURPOSE: This study aimed to investigate the potential diagnostic value of 
      miR-214, B-type natriuretic peptide (BNP), N terminal-pro BNP (NT-proBNP) and 
      soluble ST2 (sST2) in acute heart failure (AHF). METHOD: This study included 176 
      patients as the AHF group and 60 healthy subjects as the control group from 
      February 2018 to February 2020. Patients in the AHF group were classified 
      according to the New York Heart Association (NYHA) functional classification, 
      including 60 level II patients, 59 level III patients and 57 level IV patients. 
      The expression level of miR-214, BNP, NT-proBNP and sST2 of both groups were 
      recorded and analysed. RESULTS: The morbidity of cardiovascular diseases was 
      significantly higher in the AHF group than in the control group (P < .05). The 
      expression level of miR-214, BNP, NT-proBNP and sST2 in the AHF group were all 
      significantly higher than in the control group (P < .05). Besides, the expression 
      level of all the molecules in level IV was significantly higher than that of 
      level III and level II, respectively (P < .001, P < .001). In addition, the 
      expression level of all the molecules in level III was significantly higher than 
      that of level II (P < .001). The area under the ROC curve of miR-214, BNP, 
      NT-proBNP and sST2 were 0.913, 0.836, 0.849 and 0.855, respectively, indicating 
      good diagnostic value. CONCLUSION: MiR-214, BNP, NT-proBNP and sST2 can be used 
      as effective biomarkers for AHF, providing a new strategy for diagnosis and for 
      judging the severity of AHF.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Jin, Yinsheng
AU  - Jin Y
AD  - Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Wei, Shuang
AU  - Wei S
AD  - Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Yao, Lingling
AU  - Yao L
AUID- ORCID: 0000-0002-6309-2948
AD  - Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210805
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Biomarkers)
RN  - 0 (MIRN214 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Biomarkers
MH  - *Heart Failure/diagnosis
MH  - Humans
MH  - *MicroRNAs
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
EDAT- 2021/07/27 06:00
MHDA- 2021/09/22 06:00
CRDT- 2021/07/26 17:37
PHST- 2021/04/23 00:00 [received]
PHST- 2021/07/23 00:00 [accepted]
PHST- 2021/07/27 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
PHST- 2021/07/26 17:37 [entrez]
AID - 10.1111/ijcp.14643 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Oct;75(10):e14643. doi: 10.1111/ijcp.14643. Epub 2021 Aug 
      5.